electroCore, Inc. Broadens Patient Access to gammaCore with Launch of U.S. Telehealth Portal and Online Store
electroCore (Nasdaq: ECOR) has launched an online e-commerce shop in the United States for its gammaCore Sapphire™, a non-invasive vagus nerve stimulator for treating migraines and cluster headaches. This initiative enables patients to obtain prescriptions through telehealth consultations and purchase the device online. The platform, powered by Vytal, LLC, focuses on enhancing patient accessibility and engagement, aligning with the growing trend of direct-to-consumer healthcare. Chief Strategy Officer Joshua Lev emphasized that this move expands access to millions suffering from these conditions.
- Launch of e-commerce shop enhances patient access to gammaCore therapy.
- The online platform streamlines the process for prescriptions and purchases.
- Aligns with the growing trend towards direct-to-consumer healthcare.
- None.
ROCKAWAY, N.J., Jan. 11, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the launch of an e-commerce shop for patients residing in the United States. The site, which can be accessed through www.gammacore.com, allows patients to complete a telehealth consult for a prescription and purchase gammaCore Sapphire™, a non-invasive vagus nerve stimulator (nVNS) device, online.
The online store offers therapy to patients for FDA-cleared indications like migraine and cluster headache. The store platform is powered by Vytal, LLC and allows patients to obtain a prescription via telehealth consult, purchase the therapy directly from the site, have a member of the U.S. electroCore customer service team provide post-purchase video conference training, and receive the device at their doorstep.
“The launch of an online store is a tremendous step forward in our company’s cash pay, direct-to-consumer strategy,” stated Joshua Lev, Chief Strategy Officer at electroCore. “More and more patients are utilizing online channels to manage their health, and the launch of our new online store builds on the trend of patients taking control of their healthcare. We are very excited to offer patients the ability to obtain nVNS therapy from the comfort of their home. The new functionality provides direct access to millions of migraine and cluster headache sufferers who can benefit from gammaCore nVNS therapy.”
“We are thrilled to be a part of electroCore’s direct-to-consumer initiative to treat migraines and cluster headaches. Our end-to-end solution for patient access to gammaCore allows a seamless patient experience that should help patients access this unique, proven therapy,” said Jerry Gross, Founder and CEO of Vytal.
About Vytal, LLC.
Vytal is a healthcare technology company offering comprehensive, compliant technology solutions that enable manufacturers, pharmacies, provider networks, wellness ecommerce companies, and virtual health platforms to manage, grow, and scale their operations. Vytal's data-driven direct-to-consumer ecommerce platform enables healthcare manufacturers to reach more patients and boost brand awareness. For more information visit https://www.vytal.care.
About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its non-invasive vagus nerve stimulation therapy platform, initially focused on the treatment of multiple conditions in neurology. The company's current indications are the preventive treatment of cluster headache and migraine, the acute treatment of migraine and episodic cluster headache, the acute and preventive treatment of migraines in adolescents, and paroxysmal hemicrania and hemicrania continua in adults.
For more information, visit www.electrocore.com.
About gammaCoreTM
gammaCoreTM (nVNS) is the first non-invasive hand-held medical therapy applied at the neck as an adjunctive therapy to treat migraine and cluster headache through the utilization of a mild electrical stimulation to the vagus nerve that passes through the skin. Designed as a portable easy-to-use technology, gammaCore can be self-administered by patients, as needed, without the potential side effects associated with commonly prescribed drugs. When placed on a patient’s neck over the vagus nerve, gammaCore stimulates the nerve’s afferent fibers, which may lead to a reduction of pain in patients.
gammaCore (nVNS) is FDA-cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, and the acute and preventive treatment of migraine in adolescent (ages 12 and older) and adult patients. gammaCore is CE-marked in the European Union for the acute and/or prophylactic treatment of primary headache (Migraine, Cluster Headache, Trigeminal Autonomic Cephalalgias and Hemicrania Continua) and Medication Overuse Headache in adults.
gammaCore is contraindicated for patients if they:
- Have an active implantable medical device, such as a pacemaker, hearing aid implant, or any implanted electronic device
- Have a metallic device, such as a stent, bone plate, or bone screw, implanted at or near the neck
- Are using another device at the same time (e.g., TENS Unit, muscle stimulator) or any portable electronic device (e.g., mobile phone)
Safety and efficacy of gammaCore have not been evaluated in the following patients:
- Adolescent patients with congenital cardiac issues
- Patients diagnosed with narrowing of the arteries (carotid atherosclerosis)
- Patients who have had surgery to cut the vagus nerve in the neck (cervical vagotomy)
- Pediatric patients (less than 12 years)
- Pregnant women
- Patients with clinically significant hypertension, hypotension, bradycardia, or tachycardia
Please refer to the gammaCore Instructions for Use for all important warnings and precautions before using or prescribing this product.
For more information, please visit www.gammacore.com.
Forward-Looking Statements
This press release and other written and oral statements made by representatives of electroCore may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about electroCore's business prospects and clinical and product development plans; its pipeline or potential markets for its technologies; the timing, outcome and impact of regulatory, clinical and commercial developments; the Company’s business prospects in the United States (including its e-commerce initiative) and other new markets and other statements that are not historical in nature, particularly those that utilize terminology such as "anticipates," "will," "expects," "believes," "intends," other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue electroCore’s business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize gammaCore™, the potential impact and effects of COVID-19 on the business of electroCore, electroCore’s results of operations and financial performance, and any measures electroCore has and may take in response to COVID-19 and any expectations electroCore may have with respect thereto, competition in the industry in which electroCore operates and overall market conditions. Any forward-looking statements are made as of the date of this press release, and electroCore assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents electroCore files with the SEC available at www.sec.gov.
Investors:
Rich Cockrell
CG Capital
404-736-3838
ecor@cg.capital
or
Media Contact:
Jackie Dorsky
electroCore
908-313-6331
Jackie.dorsky@electrocore.com
FAQ
What is the new service electroCore announced on January 11, 2022?
How does the new e-commerce platform benefit patients with migraines?
Who powers the e-commerce shop for electroCore?
What conditions does gammaCore treat?
